Vicuron: Take the money now

Vicuron Pharmaceuticals Inc. suggests that its shareholders might ultimately have seen the $1.9 billion valuation provided in last week's takeout deal with Pfizer Inc., but there was no reason to wait with an 84% premium, in cash, on the table.

Meanwhile, the pharma company says the acquisition was driven by two things: a need to compensate for the patent expirations of antibiotics Diflucan fluconazole and Zithromax azithromycin and good synergies between the companies' anti-infective portfolios, which include the pending NDAs for anidulafungin and dalbavancin from Vicuron (MICU; NMerc:MICU)...